Initial clinical evaluation of indigenous (90)Y-DOTATATE in sequential duo-PRRT approach ((177)Lu-DOTATATE and (90)Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, (90)Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects

(177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky disease and nonhomogeneous somatostatin receptors (SSTR) distribution, owing to lower energy (Eβmax 0.497 MeV) and a shorter particle penetr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:World J Nucl Med
Autori principali: Parghane, Rahul V., Mitra, Arpit, Bannore, Trupti Upadhye, Rakshit, Sutapa, Banerjee, Sharmila, Basu, Sandip
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wolters Kluwer - Medknow 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8034792/
https://ncbi.nlm.nih.gov/pubmed/33850492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/wjnm.WJNM_52_20
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi